Literature DB >> 12093832

Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation.

Oi Shan Tang1, Jieshuang Xu, Linan Cheng, Sharon W H Lee, Pak Chung Ho.   

Abstract

BACKGROUND: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. A new route of administration of misoprostol, the sublingual route, was investigated in this study.
METHODS: One hundred women who requested legal termination of pregnancy up to 63 days were given 200 mg of oral mifepristone followed 48 h later by 800 microg (4 x 200 microg tablets) of sublingual misoprostol.
RESULTS: Ninety-four women (94%) had a complete abortion with this regimen. There was one ongoing pregnancy. The median duration of vaginal bleeding was 15 days. There were no serious complications. However, lower abdominal pain, diarrhoea, chills and fever were the commonest side-effects with incidences of 89, 42, 38 and 79% respectively.
CONCLUSIONS: The combination of mifepristone and sublingual misoprostol is effective for medical abortion up to 63 days gestation. Randomized trials are required to compare its efficacy and side-effect profile with vaginal misoprostol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093832     DOI: 10.1093/humrep/17.7.1738

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  4 in total

Review 1.  Pain management for medical abortion before 14 weeks' gestation.

Authors:  John J Reynolds-Wright; Mulat A Woldetsadik; Chelsea Morroni; Sharon Cameron
Journal:  Cochrane Database Syst Rev       Date:  2022-05-13

2.  Comparative Study of Misoprostol in First and Second Trimester Abortions by Oral, Sublingual, and Vaginal Routes.

Authors:  Deepika Nautiyal; Krishna Mukherjee; Inderjeet Perhar; Navnita Banerjee
Journal:  J Obstet Gynaecol India       Date:  2014-07-23

3.  Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls.

Authors:  Heidi Moseson; Ruvani Jayaweera; Ijeoma Egwuatu; Belén Grosso; Ika Ayu Kristianingrum; Sybil Nmezi; Ruth Zurbriggen; Relebohile Motana; Chiara Bercu; Sofía Carbone; Caitlin Gerdts
Journal:  Lancet Glob Health       Date:  2021-11-18       Impact factor: 38.927

4.  Comparison of sublingual and vaginal misoprostol for second-trimester pregnancy terminations.

Authors:  Forozan Milani; Seyede Hajar Sharami; Saeedeh Arjmandi
Journal:  J Family Reprod Health       Date:  2014-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.